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Genes required for the lysosomal degradation pathway of autophagy play key roles in 
topologically distinct cellular processes with significant physiologic importance. One of 
the first-described of these ATG gene-dependent processes is the requirement for a 
subset of ATG genes in interferon-γ (IFNγ)-induced inhibition of norovirus and 
Toxoplasma gondii replication. In this dissertation we identified novel components that 
are required for or that negatively regulate this immune mechanism. Enzymes involved in 
the conjugation of UFM1 to target proteins including UFC1 and UBA5, negatively 
regulated IFNγ-induced inhibition of norovirus replication via effects of Ern1. We identified 
and confirmed that IFNγ-induced inhibition of norovirus replication required Wipi2b, Atg9a 
and Gabarapl2 while Becn1, Atg14 and Sqstm1 were not important. The 
phosphatidylinositol-3-phosphate and ATG16L1 binding domains of WIPI2B were 
required for IFNγ-induced inhibition of norovirus replication. WIPI2 was also required for 
IFNγ-induced inhibition of Toxoplasma gondii replication in HeLa cells.  
 vii 
Moreover, we utilized an unbiased genome wide CRISPR-Cas9 screening approach to 
identify additional novel components of this immune mechanism. We identified 164 
candidate genes regulating this immune process, Uba5 among them. We identified 51 
candidate genes required for IFNγ-induced control of norovirus and significant enrichment 
of the Cul3 ubiquitin-ligase network. We confirmed Cul3 and the cullin-RING ligase 
substrate adaptor Klhl9 were required for IFNγ-induced control of norovirus. Cul3, Klhl9 
and ubiquitin localized to norovirus replication complexes containing the viral protease-
polymerase protein in infected cells. This work further delineates the mechanisms of a 
programmable form of cytokine-induced intracellular immunity that relies on an expanding 
cassette of essential ATG genes and additional novel genes pertaining to the ubiquitin 








IFNγ is a critical mediator of cell-intrinsic immunity to infectious diseases (1). IFNγ is also 
critical for inhibition of murine norovirus (herein norovirus) in myeloid cells (2–4). For 
example, components of the Stat1 and Irf1 encode transcription factors essential for IFNγ 
responses (5), and are required for robust IFNγ-induced inhibition of norovirus replication 
both in vitro in primary macrophages and in vivo (3, 6, 7). Guanylate binding proteins 
(GBPs) and immune regulated GTPases (IRGs) are interferon-stimulate-genes (ISGs) 
both required for inhibiting norovirus replication (8). In IFNγ-induced cells, GBPs and 
IRGs are found localized to the membranous intracellular compartment where norovirus 
establishes the replication complex (8). How GBPs and IRGs, or other ISGs integrate with 
cellular components to effectively target the norovirus replication complex, remains an 
open question. 
The role of autophagy genes (ATG genes herein) supporting the actions of IFNγ are 
important to survival of mammals because this cytokine plays an essential role in 
triggering cell-intrinsic immunity to intracellular bacteria, viruses and parasites. For 
example, Toxoplasms gondii replicates in a parasitophorous vacuole sequestered away 
from the cytoplasm, while norovirus replicates on the cytoplasmic face of membranes. In 
mouse, IFNγ-induced ATG gene-dependent clearance of T. gondii occurs by destruction 
of the parasitophorous vacuole (9, 10). In contrast, IFNγ inhibits norovirus replication by 
disrupting the formation and/or function of the membranous replication compartment upon 
which viral RNA synthesis occurs (4, 8–15). IFNγ-induced inhibition of T. gondii and 
norovirus requires a series of ATG genes Atg7, Atg5, Atg16l1, Atg12, Atg3, and ATG8 
family members (2, 4, 8–15). How ATG genes integrate with ISGs and or existing cellular 
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components, remains an open question. Here, we take two approaches to better 
understand IFNγ-induced immunity to intracellular pathogens: 1) An ATG gene focused 
approach to better understand ATG gene-dependent and IFNγ-induced inhibition of 
norovirus; 2) an unbiased approach to understanding any underlying biology of IFNγ-
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Genes required for the lysosomal degradation pathway of autophagy play key roles in 
topologically distinct cellular processes with significant physiologic importance. One of 
the first-described of these ATG gene-dependent processes is the requirement for a 
subset of ATG genes in interferon-γ (IFNγ)-induced inhibition of norovirus and 
Toxoplasma gondii replication. Herein we identified new genes that are required for or 
that negatively regulate this immune mechanism. Enzymes involved in the conjugation of 
UFM1 to target proteins including UFC1 and UBA5, negatively regulated IFNγ-induced 
inhibition of norovirus replication via effects of Ern1. IFNγ-induced inhibition of norovirus 
replication required Wipi2b and Atg9a, but not Becn1 (encoding Beclin1), Atg14, or 
Sqstm1. The phosphatidylinositol-3-phosphate and ATG16L1 binding domains of WIPI2B 
were required for IFNγ-induced inhibition of norovirus replication. Both WIPI2 and 
SQSTM1 were required for IFNγ-induced inhibition of Toxoplasma gondii replication in 
HeLa cells. These studies further delineate the mechanisms of a programmable form of 
cytokine-induced intracellular immunity that relies on an expanding cassette of essential 










Macroautophagy (autophagy herein) requires formation of an isolation membrane that 
envelops cytoplasmic materials, organelles or invading pathogens in a closed double 
membrane-bound autophagosome. Autophagosomes fuse with lysosomes to facilitate 
degradation of captured material (1, 2). Autophagy requires a series of autophagy genes 
(ATG genes), many of which are conserved broadly in evolution. It is now clear that these 
essential ATG genes are also required for additional topologically distinct cellular 
processes that have significant physiologic importance (3, 4, 5). Many of these 
autophagy-independent, but ATG gene-dependent, processes occur in myeloid cells. 
These include essential roles for ATG genes in the anti-microbial action of the key 
cytokine IFNγ (also referred to as Type II IFN), the deposition of the ATG8-family proteins 
on the cytoplasmic surface of phagosomes (2, 6), the fusion of lysosomes to the polarized 
ruffled membrane of osteoclasts to secrete lysosomal proteases for extracellular 
degradation of bone (7), the regulation of neutrophilic inflammation during Mycobacterium 
tuberculosis infection (8) and the inhibition of inflammatory activation of tissue-resident 
macrophages (9). Of particular note, the role of ATG genes in the actions of IFNγ are 
fundamentally important to survival of mammals because this cytokine plays an essential 
role in triggering cell-intrinsic immunity to intracellular bacteria, viruses and parasites.  
The fact that ATG genes play roles in both autophagy and topologically distinct cellular 
processes makes it imperative to further define the molecular machinery that is in 
common to, or distinguishes, these distinct cellular events. Here we focus on IFNγ-
induced ATG gene-dependent intracellular immunity to murine norovirus (norovirus 
herein) and Toxoplasma gondii (T. gondii). Inhibition of intracellular replication of these 
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pathogens requires ATG genes Atg7, Atg5, Atg16l1, Atg12, Atg3 and ATG8 family 
members (10–18). ATG3, ATG7 and the ATG5-ATG12-ATG16L1 (herein ATG5-12-16L1) 
complex are required for the ubiquitin-like conjugation system of autophagy that 
conjugates phosphatidyl-ethanolamine (PE) to localize ATG8 proteins on membranes (1, 
4). However, the topology of the intracellular events triggered by IFNγ are distinct for the 
two pathogens. T. gondii replicates in a parasitophorous vacuole sequestered away from 
the cytoplasm, while norovirus replicates on the cytoplasmic face of membranes. In 
mouse, IFNγ-induced ATG gene-dependent clearance of T. gondii occurs by destruction 
of the parasitophorous vacuole (10, 13), while in human cells this pathway limits 
replication but does not eliminate the parasite (15, 19). In contrast, IFNγ inhibits norovirus 
replication by disrupting the formation and/or function of the membranous replication 
compartment upon which viral RNA synthesis occurs (10–18).   
Here, we show that an immortalized murine macrophage-like microglial cell line (BV-2 
cells) (20) recapitulates ATG gene-dependent events in IFNγ-induced inhibition of 
norovirus replication as originally described in primary macrophages. Using CRISPR-
Cas9 screening, we identified additional positive and negative regulators of this process.  
Ufc1 and Uba5 regulated IFNγ inhibition of norovirus replication. In contrast, Atg9a and 
Wipi2b were required for efficient IFNγ-induced inhibition of norovirus replication. The  
ATG16L1- and phosphatidylinositol 3-phosphate (PtdIns(3)P)-binding domains of WIPI2B 
were required for efficient IFNγ-induced inhibition of norovirus replication. WIPI2 was also 
required for IFNγ-induced inhibition of T. gondii replication in human cells. In contrast to 
findings in the norovirus system, SQSTM1 (herein P62) was required for IFNγ-induced 
inhibition of T. gondii replication. Thus, components of the autophagy machinery outside 
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of the ubiquitin-like conjugation systems involving the ATG5-12-16L1 complex are 
important components of a cellular immune mechanism used by IFNγ to block intracellular 
pathogen replication, potentially identifying targets for modulation of this type of immunity.  
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Results 
IFNγ inhibits norovirus replication in BV-2 cells in a Stat1- and Irf1-dependent manner. 
BV-2 cells are permissive for replication of murine norovirus strain MNoVCW3 (21), 
allowing us to test whether, in these cells, norovirus replication was inhibited by 
recombinant IFNγ as measured by plaque assay and cellular ATP content as a proxy for 
cell viability (Fig. 6). Pretreatment of BV-2 cells with IFNγ decreased MNoVCW3 replication 
~5000-fold (Fig. 1A) and cytopathicity by 50% (Fig. 1B). Stat1 and Irf1 encode 
transcription factors essential for IFNγ responses (22), and are required for robust IFNγ-
induced inhibition of norovirus replication both in vitro in primary macrophages and in vivo 
(23–25). To determine whether these transcription factors were required for IFNγ-induced 
inhibition of MNoVCW3 replication in BV-2 cells we generated two independent clonal Stat1 
or Irf1 knockout BV-2 cell lines (Stat1-/-, Irf1-/-)(Fig. 1A and B). Throughout this work we 
confirmed deletion of genes in cell lines using next generation sequencing (Table 1). IFNγ 
failed to efficiently inhibit norovirus replication and cytopathicity in either Stat1-/- or Irf1-/- 
cells (Fig. 1A, 1B), faithfully replicating the requirement for these genes in primary cells.  
The ATG5-12-16L1 complex is required for IFNγ-induced inhibition of norovirus 
replication in BV-2 cells. The ATG5-12-16L1 complex is crucial for IFNγ-induced control 
of MNoVCW3 in bone marrow-derived murine macrophages (11). Using Atg5 knockout BV-
2 cells (Atg5-/-) (26, 27) we confirmed that Atg5 was required for IFNγ-induced inhibition 
of MNoVCW3 replication (Fig. 1C). To further define the role of the ATG5-12-16L1 complex 
we generated two independent clonal knockout BV-2 cell lines for each of Atg12 and 
Atg16l1 (Atg12-/-, Atg16l1-/-) (Table 1)(27). IFNγ failed to efficiently inhibit MNoVCW3 
replication in cells lacking either Atg12 or Atg16l1 (Fig. 1C). While there were significant 
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decreases IFNγ inhibition of norovirus replication in cells lacking Atg12 or Atg16l1, there 
was variation between clonal knockout cell lines. Deep sequencing confirmed saturating 
indel frequencies in both Atg12 and Atg16l1 in clonal knockout cells (Table 1) supporting 
a role for Atg12 and Atg16l1 in IFNγ inhibition of MNoVCW3 replication in these cells.  
The ATG genes Becn1 and Atg14 are not required for IFNγ-induced inhibition of norovirus 
replication. Certain upstream components of the autophagy pathway are not required for 
IFNγ-induced inhibition of norovirus or T. gondii replication (10, 11, 15, 16). To confirm 
these observations in BV-2 cells, we determined whether IFNγ efficiently inhibits 
MNoVCW3 replication in clonal Atg14-/- BV-2 cells (26, 27) and clonal Becn1-/- cell lines 
(27). Neither Atg14 nor Becn1 were required for IFNγ-induced inhibition of MNoVCW3 
replication (Fig. 1D). Together with the data on the role of Stat1, Irf1, Atg5, Atg12 and 
Atg16l1 above these data support the validity of BV-2 cells as a model to further define 
mechanisms of IFNγ-induced ATG gene-dependent immunity to norovirus. 
CRISPR screen design for identification of genes involved in IFNγ-induced inhibition of 
norovirus cytopathicity in BV-2 cells. We used CRISPR screening to determine the 
possible contribution of genes selected for their potential roles in autophagy or other ATG 
gene-dependent cellular processes to IFNγ action. We designed an autophagy sgRNA 
library containing 1 to 4 independent guides targeting 695 candidate genes (Table S2). 
We included 300 guides with no known target as controls (2979 guides total) (28). Genes 
were selected using three criteria: (i) present in the autophagy interaction landscape, 
including the baits used, as defined by Behrends et al. (29); (ii) murine genes related to 
autophagy using GO ontology (30, 31); (iii) murine genes corresponding to human genes 
related to autophagy using GO ontology (30, 31).  
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To enhance the sensitivity of this CRISPR screen we targeted generation of a cell pool 
with each guide represented by ~2000 cells (32). After experimental selection (Fig. S2A), 
we quantified guides by DNA sequencing and determined the significance of differences 
in guide frequencies in different comparisons using STARS and negative binomial 
analysis (21, 26–28, 33) with a threshold of FDR < 0.1 to identify genes for further 
consideration (27).  
Identification of genes required for cell survival in the absence of norovirus infection. The 
effects of genes required for cell survival or proliferation may obscure identification of 
those required for a phenotype, especially when cell death is part of the biology being 
studied as is the case for norovirus replication and IFNγ treatment (21, 27, 28). We 
therefore identified differences in guide frequency between the original cell library and 
cells passaged under mock conditions (Fig. 2A, Table 3) as well as between cells 
passaged under mock conditions compared to those treated with IFNγ at two doses (Fig. 
2B and 2C, Table S5). Mock passage did not enrich guides for any gene but decreased 
guides for 52 genes, suggesting that these are essential genes for survival of BV-2 cells 
under these conditions. Among the targeted genes were Cdc37, Adsl, and Cct2. 
Mutations in ADSL result in the rare autosomal recessive disorder Adenylosuccinate 
lyase deficiency (34) while CCT2 mutations evoke the rare disease Leber Congenital 
Amaurosis (35). We compared these candidate essential genes to those identified in 
Project Achilles (36–38). Three of 52 genes lacked a human homolog and one did not 
have specific guides in Project Achilles. Therefore 48 candidate essential genes were 
considered for this comparison (Table 4). 43 of 48 (95%) depleted genes were considered 
common essential among immortalized cells (Table 4) (36–38) thus validating our 
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screening approach. We deprioritized further analysis of genes whose guides were 
depleted under control conditions. 
Identification of genes enriched or depleted in the presence IFNγ. IFNγ treatment at a 
dose of 1 U/mL enriched guides for 7 genes (Fig. 2B, Table 5). Escalation of the IFNγ 
dose to 10 U/mL enriched guides for 20 genes (Fig. 2C, Table 5). Among the targeted 
genes were Eif5, Polrmt, Eif3a, Polr3a, Eif4g2 and Eif4e (Fig. 2B and 2C, Table 5). These 
genes regulate mRNA translation and immune cell activation (39–41). IFNγ treatment at 
1 U/mL depleted guides for 25 genes (Fig. 2B, Table 5), and at a dose of 10 U/mL 
depleted guides for 24 genes (Fig. 2C, Table 5). We observed agreement at the gene-
level between treatment with 1 U/mL or 10 U/mL IFNγ, with a Pearson’s correlation of 
0.70 (Fig. 2D). Among the targeted genes were Traf2, Tbk1, Ikbkg, Tank, Ei24, Map3k7, 
Atg5 and Atg14 (Fig. 2B and C, Table 5). Traf2, Tbk1, Ikbkg, Tank, Ei24 and Map3k7 
regulate the tumor necrosis factor receptor signaling pathway (42–44). Consistent with 
these results, IFNγ-induced cell death in BV-2 cells is mediated by tumor necrosis factor 
(27). Our results confirmed the critical role for Atg14 and Atg5 in inhibiting IFNγ-induced 
cell death in BV-2 cells (Fig. 2C, Table 5) (27). Guides for Wipi2, Rb1cc1 (also known as 
Fip200), Atg9a, Atg101 and Atg12 were also depleted, though these genes were not 
reported to protect BV-2 cells from IFNγ-induced cell death (Fig. 2B and 2C, Table 5) 
(27).  
Identification of genes that enhance IFNγ-induced inhibition of norovirus induced 
cytopathicity. Guides for 18 genes (Fig. 3A, Table 6) were enriched in IFNγ-treated and 
norovirus infected cells compared to mock conditions. Among the targeted genes were 
G3bp1, Sptcl1 and Sptcl2 which are required for efficient norovirus replication (21, 45–
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47). Among the genes identified as candidates for enhancing IFNγ-induced inhibition of 
norovirus replication were Iqgap1 and Ufc1 (Fig. 3A, Table 6). Deficiency of IQGAP1 in 
human monocytic cells results in hyperactive type I IFN responses to cytosolic 
nucleotides (48). Ufc1 and Uba5 encode enzymes in the ubiquitin-like system that 
covalently conjugates UFM1 to target proteins (UFMylation herein) (26, 49–51). 
UFMylation is required to maintain ER homeostasis, so that in the absence of UFMylation 
consequent ER stress can lead to overactivation of IFNγ responses (26). We therefore 
quantified the effects of IFNγ on norovirus replication in cells lacking Ufc1 or Uba5 (Ufc1-
/-, Uba5-/-) (26). IFNγ more potently inhibited norovirus replication in these cells (Fig. 3D 
and E) as shown by diminished potency of IFNγ upon expression of wild type UFC1 
(Ufc1WT or Uba5WT), but not the enzymatically dead versions of these proteins (Ufc1ΔC116A; 
Uba5ΔC248A) (Fig. 3D and E) (26). UBA5 contains a UFM1 interaction motif disrupted upon 
the mutations of W340A/L344A (Uba5ΔUFIM) (26, 49, 50). Disruption of this motif prevented 
UBA5 from rescuing the increased IFNγ potency observed in Uba5-/- cells (Fig. 3E). 
Consistent with data from Balce et al., Ern1 deletion reversed effects on IFNγ potency 
observed in Uba5-/- cells, consistent with a role for this aspect of the ER stress response 
in modulating IFNγ action (Fig. 3F) (26).  
Identification of candidate genes required for efficient inhibition of norovirus-induced 
cytopathicity by IFNγ. We reasoned that guides depleted after pre-treatment with 1U/mL 
IFNγ and infection with norovirus compared to mock conditions might represent genes 
required for IFNγ-induced inhibition of norovirus infection.  We compared guide 
frequencies between mock and 1U/mL IFNγ + MNoVCW3 infection, reasoning that guides 
decreased in cells surviving MNoVCW3 infection of IFNγ-treated cells might have a role in 
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IFNγ-induced inhibition of MNoVCW3 replication (Fig. 3A). We observed intermediate 
agreement of gene-level results, with a Pearson’s correlation of 0.45 between 1 U/mL 
IFNγ treatment alone compared to 1U/mL IFNγ + MNoVCW3 infected cells (Fig. 3B). 
Guides for 32 genes (Fig. 3A, Table 6) were decreased in frequency in IFNγ + MNoVCW3 
infected cells. Wipi2 and Atg9a had not been previously identified as required for ATG 
gene dependent innate immunity. We generated one clonal BV-2 cell line lacking Wipi2 
(Wipi2-/- ; clone 1) (Table 1) and one heterozygous cell line lacking Wipi2 (Wipi2-/+ ; clone 
2) (Table 1). We also examined BV-2 cells lacking Atg9a (Atg9a-/-) (Table 1) (26). Wipi2 
and Atg9a were required for efficient IFNγ-induced inhibition of MNoVCW3 replication (Fig. 
4A), indicating that they constitute key components of the intracellular mechanisms used 
by IFNγ to inhibit norovirus infection.  
ATG16L1 and PtdIns(3)P binding domains of WIPI2 are required for IFNγ-induced 
inhibition of norovirus replication. We analyzed the role of WIPI2 in greater detail because 
it interacts with ATG16L1 (52, 53), which plays a key role in IFNγ-induced inhibition of 
norovirus replication (Fig. 4B) (11, 16).  We defined the effects of the R108E/R125E 
(DRERE) mutations that inhibit binding to ATG16L1, the R224T/R225T (DFTTG) 
mutations that inhibit binding to PtdIns(3)P, and the double mutant DRERE/DFTTG (Fig. 
4B) (52). We stably expressed these proteins and wild type WIPI2B in Wipi2-/- (clone 1) 
cells and assessed protein expression by western blot analysis (Fig. 4C), probing for an 
N-terminal epitope tag, revealing equivalent expression of the different constructs (Fig. 
4C). Expression of WIPI2B rescued the capacity of IFNγ to inhibit norovirus infection in 
Wipi2-/- cells (Fig. 4D). In contrast, neither WIPI2BDRERE nor WIPI2BDFTTG rescued 
inhibition of MNoVCW3 after IFNγ-treatment (Fig. 4D). The double mutant 
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WIPI2BDREREDFTTG protein also failed to restore IFNγ activity (Fig. 4D). Thus WIPI2B 
binding to both ATG16L1 and PtdIns(3)P was necessary for immune control of norovirus 
by IFNγ.  
Determining the generality of a role for WIPI2 in IFNγ-induced ATG gene-dependent 
immunity. The original reports of IFNγ-induced ATG gene-dependent immunity 
demonstrated targeting of both norovirus, a cytoplasmic RNA virus, and the apicomplexan 
parasite T. gondii (10, 11). To determine whether WIPI2 plays a more general role in 
IFNγ-induced immunity, we quantitated T. gondii replication within the parasitophorous 
vacuole (PV) in parental and two independent WIPI2-/- human HeLa cells (Table 1), using 
a type III parasite that is susceptible to ATG gene-dependent IFNγ-induced growth control 
(15, 19). T. gondii multiplies by binary fission with a half-life of ~8 hours, generating 
vacuoles of different sizes containing clusters of 1 to ≥ 8 parasites over 24 hours. 
Parasitophorous vacuoles become labeled by ubiquitin in IFNγ-treated cells (15). 
Ubiquitin-positive vacuoles are targeted in an ATG gene-dependent manner resulting in 
smaller vacuoles and decreased numbers of parasites per vacuole (15), we therefore 
counted parasites per ubiquitin-positive vacuole in wild type and WIPI2-/- HeLa cells (Fig. 
5A) (15). In wild type cells, we did not observe a growth restriction phenotype in PVs 
lacking ubiquitin (Fig. 5A, left), however most ubiquitin-positive vacuoles contained only 
1 parasite, indicative of IFNγ-induced growth restriction (Fig. 5A). In the absence of either 
ATG16L1 (as expected, (13, 15)) or WIPI2, IFNγ-induced growth restriction was reversed 
and fewer PVs containing 1 parasite were observed (Fig. 5A) while the majority containing 
≥8 parasites (Fig. 5A). Thus, as for ATG16L1, the role of WIPI2 in IFNγ-induced inhibition 
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of intracellular replication extends from a cytoplasmic RNA virus to an intravacuolar 
apicomplexan parasite.  
P62 in required for IFNγ-induced inhibition of T. gondii in human HeLa cells but not 
required for IFNγ-induced inhibition of norovirus replication in BV-2 cells. In murine cells, 
the ubiquitin binding protein P62 is recruited to vacuoles containing T. gondii in an IFNγ-
dependent manner but is ultimately dispensable for inhibiting replication of the parasite 
(54). In human cells, P62 is also recruited to parasitophorous vacuoles in an IFNγ-
dependent manner (15) but its requirement for the restriction of T. gondii replication is 
unknown. Therefore, we generated clonal P62-/- HeLa cells (Table 1) and observed that 
P62 was required for IFNγ-induced inhibition of T. gondii (Fig. 5B) but was not required 
for IFNγ-induced inhibition of MNoVCW3 replication in clonal p62-/- BV-2 cells (Fig. 
5C)(Table 1). Taken together, these data suggest the requirement for P62 in IFNγ-




Intracellular pathogens present diverse challenges to the immune system because they 
hijack different aspects of cell biology to their own advantage. IFNγ is a central mediator 
of innate and adaptive immunity, in part via orchestrating the activities of populations of 
immune cells. However, IFNγ is also responsible for cell-intrinsic immunity to intracellular 
pathogens via induction of transcriptional and other cellular pathways that create an 
environment inside cells that is hostile to invading pathogens. Understanding the 
molecular and cellular mechanisms for this process is important for defining mechanisms 
of immunity to infection. We report herein additional cellular genes that regulate 
intracellular immunity and identify components of the autophagy machinery including 
Atg9a and Wipi2b that play an autophagy-independent role in IFNγ-induced intracellular 
immunity to T. gondii and norovirus. 
We and others have shown that the mechanisms of IFNγ-induced intracellular immunity 
to norovirus and T. gondii do not require autophagy as a degradative function, but 
nevertheless require essential ATG genes involved in the ubiquitin-like systems that 
conjugate ATG8 family proteins to PE during autophagy (10–13, 15, 16, 18, 55). The 
involved proteins include ATG7, which triggers the lipidation of ATG8 family proteins, 
ATG3 which complexes with ATG8 family proteins to foster their lipidation, and the E3-
ligase-like ATG5-12-16L1 complex (10–13, 15, 16, 18, 55), which directs lipidation of 
ATG8 family proteins to appropriate sub-cellular locations. The ATG8 family comprises 
LC3 and GABARAP proteins involved in various aspects of autophagy and non-
autophagic cellular processes (1, 4, 56, 57). In many of these functions, ATG8 proteins 
are localized on membranes by lipidation dependent on the ATG5-12-16L1 complex.   
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It is notable that the cellular membranes targeted by these ATG genes are quite distinct 
for T. gondii and norovirus. T. gondii survives and replicates via binary fission inside a 
single membrane-bound vacuole created when it invades the cell. Replication occurs 
sequestered away from the cytoplasm. In contrast, norovirus replication occurs on the 
cytoplasmic face of intracellular membranes rearranged into a topologically complex 
replication complex responsible for orienting viral proteins and nucleic acids for efficient 
replication and assembly. Nevertheless, these two topologically distinct processes are 
interdicted by IFNγ in a manner dependent on a common set of ATG genes. This ATG 
gene-dependent form of intracellular immunity is triggered by IFNγ binding to its receptor 
to induce Stat1 protein phosphorylation, Irf1 activation and the transcriptional induction of 
effector proteins (11, 16, 25, 58).     
ATG genes required for this form of IFNγ-induced immunity provide clues as to the 
mechanisms involved, but so do the ATG genes that are not required. We confirmed the 
previously reported lack of a role for Atg14 in IFNγ-induced inhibition of norovirus 
replication (16). This is a key observation because ATG14 is an essential component of 
the C1 form of the hetero-tetrameric Class III PI3Kinase complex required for autophagy 
initiation (1, 3). ATG14 is also not required for control of T. gondii in IFNγ-treated human 
HeLa cells (15). The C1 complex comprises ATG14, VPS15, VPS34 and Beclin 1, while 
the C2 complex substitutes UVRAG for ATG14 (1, 4, 5). These lipid kinases generate 
PtdIns(3)P on membranes including the isolation membrane to initiate autophagy. While 
ATG14 is a component of only one form of the Class III PI3Kinases involved in autophagy, 
Beclin 1 is a core member of all known autophagy-related Class III PI3Kinases. We report 
here that the gene Becn1 was not required for IFNγ-mediated inhibition of norovirus 
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replication.  Of note, the specificity of our observations demonstrating a lack of a role for 
Atg14 and Becn1 in IFNγ-induced immunity is supported by the observation that the same 
cell lines used here were used to show that Becn1 and Atg14 are required for protection 
against IFNγ-induced cell death in BV-2 cells (27). It is notable that there is overlap 
between the genes required to prevent cell death induced by IFNγ, and those required 
for IFNγ to inhibit norovirus replication. However, the mechanisms of IFNγ-induced 
inhibition of norovirus replication and prevention of cell death likely differ because 
prevention of IFNγ-induced cell death requires Atg14 and Becn1 (27), while prevention of 
norovirus replication did not. Together these data show that the classical PI3K complexes 
involved in autophagy are not required for this form of intracellular immunity. 
 
Cellular mechanisms of ATG gene-dependent immunity to norovirus and T. gondii. 
The mechanism by which ATG proteins inhibit replication of both norovirus and T. gondii 
in IFNγ-treated cells involves the recruitment of IFN-inducible GTPases to the intracellular 
membranes responsible for supporting pathogen replication (14, 16, 55, 58–60). While 
the genes encoding sub-families of the interferon-γ-inducible immunity-related GTPase 
(IRGs) differ between humans and mice (55, 61), IRGs and guanylate-binding proteins 
(GBPs) in mice, and GBPs in humans (62) are required for IFNγ-induced inhibition of the 
replication of both norovirus and T. gondii, as well as Chlamydia (58, 63, 64). In contrast 
to species variations in IFN-induced GTPases that act downstream of ATG proteins, the 
role of the ATG5-12-16L1 complex is conserved between humans and mice for this form 
of IFNγ-induced intracellular immunity. There appear to be conserved sequential events 
that result in targeting norovirus and T. gondii-related cellular membranes despite the 
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striking differences in topology between the cellular compartments used by these two 
pathogens. First, the ATG5-12-16L1 complex is recruited to the relevant membranes 
followed by deposition of lipidated forms of the ATG8 family proteins. This is followed by 
recruitment of IFN-inducible GTPases to the target membranes (reviewed in (58)). Less 
well defined are events prior to ATG5-12-16L1 recruitment and those that occur after 
recruitment of IFNγ-induced immune effectors to pathogen-related membranes (58).  
 
New components of ATG gene-dependent immunity  
We validated the BV-2 cell system for studies of IFNγ-induced inhibition of norovirus via 
demonstration of roles for Stat1, Irf1 and the ATG5-12-16L1 complex, confirming the 
expected role of these genes observed in other systems (11, 16, 23, 25). Validation of 
BV-2 cells as a system to study ATG gene-dependent immunity enabled screening of a 
set of autophagy-related genes using CRISPR-targeted gene disruption. Mock or IFNγ 
treatment alone revealed genes essential for cell survival, which were not studied further. 
Analysis of cells treated with IFNγ and infected with norovirus revealed genes essential 
for efficient norovirus replication (21, 45–47) and the genes that regulate responses to 
IFNγ such as Ufc1 and Uba5. We further showed that Wipi2 and Atg9a are required for 
efficient IFNγ-induced inhibition of norovirus replication; we were able to confirm a role 
for WIPI2B in control of T. gondii in addition to norovirus replication. Intriguingly, Atg9a 
was previously found to be dispensable for the localization of p62, GBPs, Irga6 and 
ubiquitin to the parasitophorous vacuole of T. gondii in mouse embryonic fibroblast (17) ; 
p62 was also found to be dispensable for inhibiting replication of the parasite in the murine 
cells (54). However, we found that P62 was required for IFNγ-induced inhibition of T. 
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gondii in HeLa cells, but not for norovirus replication in murine cells. Thus, while there are 
shared ATG genes involved in IFNγ-induced immunity to these two pathogens, there are 
proteins such as ATG9A and P62, which may play pathogen- or cell type-specific role in 
these topologically distinct cellular compartments in different experimental systems.  
 
Role of Atg9a in IFNγ-induced ATG gene-dependent immunity. 
Atg9a plays its role in autophagy via provision of lipids to developing autophagosomes 
via recruitment of ATG9A-positive small vesicles (52, 57, 65). While the role for Atg9a 
demonstrated here likely involves these small vesicles, the regulation of Atg9a in IFNγ-
induced intracellular immunity appears to differ from its regulation during autophagosome 
formation. In murine cells neither the unc-5-like kinases ULK1 nor ULK2, which are 
required for initiation of autophagy, are required for IFNγ-mediated inhibition of norovirus 
replication (16, 57). This is particularly interesting since the role of ATG9A trafficking in 
autophagy is tightly regulated by ULK1 kinase (57). This suggests that the regulation of 
Atg9a function in IFNγ-induced ATG gene-dependent immunity is likely via a regulatory 
cascade distinct from that utilized to regulate the role of Atg9a in autophagy. 
Our data that Atg9a plays a key role in IFNγ-mediated inhibition of norovirus infection may 
be explained by the finding that deletion of ATG9 mRNA enhances induction of iNOS 
protein expression by IFNγ (26). Thus, the role of Atg9a might be either direct through 
action of this protein on pathogen-related intracellular membranes or indirect through 
changes in IFNγ signaling, or both.  Our findings of a negative regulatory role for the 
UFMylation activity of the UFC1 and UBA5 enzymes is likely due to such an indirect effect 
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on IFNγ signaling, but in this case likely due to the enhancement of IFNγ response via 
Ern1-dependent ER stress responses that occur when UFMylation is inhibited (26).   
 
Role of WIPI2B in IFNγ-induced ATG gene-dependent immunity. 
The role of Wipi2b in our system may inform how the ATG5-12-16L1 complex is recruited 
to intracellular membranes during IFNγ-induced ATG gene-dependent intracellular 
immunity. WIPI2B binds to both PtdIns(3)P in cellular membranes and to ATG16L1, and 
is important for intracellular targeting and clearance of Salmonella enterica serovar 
Typhimurium via the recruitment of the Atg12-5-16L1 complex to cellular membranes 
followed by LC3 lipidation and the formation of autophagosomal membranes to engulf the 
bacteria (52). We found that amino acids required for WIPI2B to interact with both 
ATG16L1 and PtdIns(3)P were required for IFNγ-induced inhibition of norovirus 
replication. One explanation for these findings is that WIPI2B is upstream of the effects 
of the ATG5-12-16L1 complex, perhaps by binding cellular lipids on target membranes 
and then recruitment of the ATG5-12-16L1 complex via binding to ATG16L1 as observed 
for its role in degradative autophagy (52). This finding presents an interesting conundrum 
in that we found that Beclin 1, an essential component of the Class III Pi3Kinases that 
generate PtdIns(3)P required for autophagy, is not required for IFNγ-induced ATG gene-
dependent inhibition of norovirus replication while, WIP2B and the ATG5-12-16L1 
complex are required. Interestingly, activation of Beclin 1-depedent processes is not 
sufficient to target the parasitophorous vacuole inhabited by T. gondii for ATG gene-
dependent immunity (15). These observations open new questions on how pathogen-
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related membranes become labelled with specific phospholipids and in turn recruit ATG 
proteins.    
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Materials and Methods 
 
Cells 
BV-2, HEK293T and HeLa cells were cultured in Dulbecco’s Modified Eagle Medium 
(DMEM, Gibco) with 10% fetal bovine serum (FBS) and 1% HEPES. BV-2 Cas9 cell lines 
were generated using standard protocols (21). Stat1-/-, Irf1-/-, Atg12-/-, Atg16l1-/-, Wipi2-/- , 
p62-/-, WIPI2-/- and P62-/- cells were generated by introducing Cas9 and gRNAs into BV2 
or HeLa cells by nucleofection. For selection, 5 μg/mL puromycin (Thermofisher) and 5 
μg/mL blasticidin (Thermofisher) was added to BV-2 cells. 
BV-2 mutant cell lines were generated at the Genome Engineering and iPSC center at 
Washington University School of Medicine (21). sgRNAs (Table 1) were nucleofected with 
Cas9 into wild type BV2 cells and clones were screened for indels by sequencing the 
target region with Illumina MiSeq at approximately 500x coverage. Indel signature 
frequency was determined using an in-house algorithm (GEiC, Washington University 
School of Medicine, St. Louis, MO). 
For cDNA expression of WIPI2B proteins cells were transduced with lentivirus carrying 
the gene of interest with an N-terminal 3X Ty1 tag (Table 7) on the pCDH-CMV-MCS-
T2A-Puro backbone (CD522A-1, System Biosciences). cDNA expression of ATG proteins 
has been previously described (21, 26, 27). 
 
Viruses and viral assays 
MNoVCW3 (Gen bank accession no. EF014462.1) was generated by transfecting a 
molecular clone (66) into HEK293T cells (P0 stock), which was passaged on BV-2 cells. 
After two passages, infected cells were frozen at -80C and thawed, cleared of cellular 
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debris and virus was concentrated by tangential flow filtration. For infection, WT or 
knockout BV-2 cells were seeded at 104 cells/well of a 96-well plate. After 8 hours, cells 
were treated with 1U/mL of IFNγ (BioLegend). 16 hours later MNoVCW3 was added at an 
MOI 5.0. Infected cells were harvested at 24 hpi and frozen at -80°C prior to plaque assay. 
For cell viability CellTiter-Glo reagent (Promega) was added to wells of a 96-well plate, 
incubated for 10 minutes at room temperature and then cellular ATP content was 
measured.  Viral titers were determined in triplicate by plaque assay on BV-2 cells. BV-2 
cells were seeded at 2 x 106 cells/well of a six-well plate and 24 hours later 100uL of 10-
fold serially diluted samples were applied to each well for 1 hour with orbital rocking at 
room temperature. Viral inoculum was aspirated, and 2 ml of warmed MEM containing 
10% FBS, 2mM L-Gluatmine, 10 mM HEPES, and 1% methylcellulose was added. Plates 
were incubated for 48-60 hours prior to visualization after staining with 0.2% crystal violet 
in 20% ethanol. 
 
Antibodies and western blots 
Cell lysates were run under reducing conditions on an Any kD™ Mini-PROTEAN® TGX 
Stain-Free™ Protein Gel (BioRad) and imaged using a ChemiDoc imaging system 
(Biorad). WIPI2B proteins were tagged with three copies of Ty1 on the N terminus 
(Brookman et al., 1995). Anti-Ty1 antibody (ThermoFisher #MA5-23513) was used at 
1:1000. Anti-Mouse HRP (Jackson Immuno Research Laboratories #315-035-003) was 
used at 1:10,000. 
 
Autophagy CRISPR-Cas9 subpool generation and screen  
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1.4x107 BV-2-Cas9 cells (21, 26, 27) were transduced with a lentivirus stock (transduction 
efficiency 40%) resulting in 6 x106 cells. 36 hours later puromycin was added and 
transduced cells selected for five days. Five days later 1x107 cells were harvested and 
DNA isolated for sequencing (QIAamp DNA Blood Midi Kit, Qiagen). For each 
experimental condition (mock, IFNγ, and IFNγ + MNoVCW3) 1x107 cells were seeded in a 
15cm2 dish. Eight hours later, cells were treated with media or 1 U/ml IFNγ. After 16 hours 
cells were either mock infected or infected with MNoVCW3 at an MOI of 5.0. Cells were 
harvested 24 hour later for isolation of DNA for sequencing and assessment of cell 
viability (Trypan blue exclusion). Genomic DNA was sequenced and analyzed (21, 26, 
27). Volcano plots were generated using the hypergeometric distribution method 
(https://github.com/mhegde/volcano_plots) and screen results were analyzed using 
STARS (https://portals.broadinstitute.org/gpp/public/software/stars). 
 
T. gondii growth restriction assay 
HeLa cells were treated with 100 U/ml IFNγ for 24 hours, infected with tachyzoites, and 
washed 2 hours later to remove extracellular parasites. Cells were fixed in 4% 
formaldehyde 24 hours later and T. gondii localized using antibody against the RH strain 
tachyzoites (67) and ubiquitin was localized using mouse antibody clone FK2 (04-263; 
EMD Millipore Corporation). Parasites were enumerated per parasitophorous vacuole 
(PV) from 30 PV on three individual coverslips from three independent experiments. 
 
Quantification and Statistical Analysis 
 30 
Data were analyzed with Prism 7 software (GraphPad Software, San Diego, CA). Volcano 
plot and Pearson visualizations were generated using R-studio (Integrated Development 
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Figure 1: Stat1, Irf1 Atg5, Atg12 and Atg16l1 are required for IFNγ-induced 
inhibition of norovirus replication in BV-2 cells, Atg14 and Becn1 are not. (A) Plaque 
assay of WT, Irf1-/- and Stat1-/- BV-2 cells as described in (Fig. 6). (B) Viability assay of 
WT, Irf1-/- and Stat1-/- BV-2 cells as described in (Fig. 6). (C) Plaque assay of WT, Atg5-/-
, Atg12-/- and Ag16l1-/- BV-2 cells as described in (Fig. S1A). (D) As in (Fig. 6) for WT, 
Atg14-/- and Becn1-/- BV-2 cells. Average data pooled from 2-3 independent experiments 
are represented as means ± SEM. P value ≤ 0.05 (*), ≤ 0.01(**), ≤0.001 (***), ≤ 0.0001 
(****) were considered statistically significant. ns, not significant. P value determined by 
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Figure 2: Identification of genes required for viability in passage or IFNγ-treated 
BV-2 cells. (A) Volcano plot of mock treatment guides enriched or depleted relative to 
five days post puromycin selection. (B) Volcano plot of guides enriched or depleted after 
1U/mL IFNγ treatment relative to mock treatment. (C) as in (B) for 10U/mL IFNγ treatment. 
(D) Average log2 fold change (LFC) of 1U/mL IFNγ condition versus LFC of 10U/mL IFNγ 
condition. Pearson correlations are indicated. For volcano plots the LFC of all sgRNAs 
for each gene is plotted against the –log10(p-value) for each gene. Blue and red 
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highlighted genes in (A) (B) (C) represent a STARS score with FDR < 0.01, dark grey 





Figure 3: Identification of genes required for of IFNγ-induced norovirus 
cytopathicity in BV-2 cells. (A) Volcano plot of guides enriched or depleted after 1U/mL 
IFNγ + MNoVCW3 infection relative to mock treatment. (B) Average LFC of 1U/mL IFNγ 
condition versus LFC of 1U/mL IFNγ + MNoVCW3 condition. (C) Plaque assay of 
Ufc1VECTOR, Ufc1WT, Ufc1ΔC116A BV-2 cells as described in (Fig. 6). (D) Plaque assay of 
Uba5VECTOR, Uba5WT, Uba5ΔUFIM, Uba5ΔCA BV-2 cells as described in (Fig. 6). (E) Plaque 
assay of BV-2WT, BV-2Ern1 guide 1, BV-2Ern1 guide 2, Uba5VECTOR, Uba5Ern1 guide 1, Uba5Ern1 guide 
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2 as described in (Fig. 6). For volcano plots the average log2 fold change (LFC) of all 
sgRNAs for each gene is plotted against the –log10(p-value) for each gene. Blue and red 
highlighted genes in (A) represent a STARS score with FDR < 0.01, dark grey genes 
represent non-targeting guides. Values in (C) (D) (E) represent means  ± SEM from two 
to three independent experiments. P value ≤ ≤0.001 (***), 0.0001 (****) were considered 
statistically significant. ns, not significant. P value determined by 2-way ANOVA with 





Figure 4: ATG16L1 and PtdIns(3)P binding domains of WIPI2B are required for 
IFNγ-induced inhibition of norovirus cytopathicity in BV-2 cells. (A) Plaque assay of 
WT, Atg9a-/- and Wipi2-/- BV-2 cells. (B) Schematic of WIPI2B complementation in clone 
1 Wipi2-/- BV-2 cells. (C) Western blot detection of TY1 epitope in WIPI2B complemented 
cells. (D) Viability assay of Wipi2VECTOR, Wipi2WT, Wipi2ΔRERE, Wipi2 ΔRERE and Wipi2ΔRERE 
ΔFTTG BV-2 cells as described in (Fig. 6). Values in (A) and (D) represent means ± SEM 
from two to three independent experiments. P value ≤ 0.05 (*), ≤ 0.01(**), ≤0.001 (***), ≤ 
0.0001 (****) were considered statistically significant. ns, not significant. P value 
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Figure 5: WIPI2 and P62 are required for IFNγ-induced growth restriction of T. 
gondii in HeLa cells, p62 is not required for IFNγ-induced growth restriction of 
norovirus in BV-2 cells. (A) WT, ATG16L1-/- and WIPI2-/- cells were treated with IFNγ 
and infected with T. gondii. Parasites within ubiquitin positive (+) and ubiquitin negative (-
) vacuoles were counted by immunofluorescence microscopy. (B) as in (A) with WT, 
ATG16L1-/- and P62-/- cells. (C) Plaque assay of WT and p62-/- BV-2 cells as in (Fig 6). 
Values in (A) (B) (C) represent means ± SEM from two to three independent experiments. 
Significance shown for vacuoles containing 1 parasite per vacuole. P value ≤ 0.05 (*), ≤ 
0.01(**), ≤0.001 (***), ≤ 0.0001 (****) were considered statistically significant. ns, not 
significant. ns, not significant. For T. gondii assay, P value determined by 2-way ANOVA 
with Tukey’s multiple comparison test; for plaque assay P value determined by 2-way 
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Figure 6. Schematic for seeding, treatment and norovirus infection. (A) Experimental 

















Figure 7. Autophagy CRISPR library screen design. (A) BV-2-Cas9 cells transduced 
with the Autophagy CRISPR library were collected for the following conditions: five days 
post puromycin selection, mock treatment, 1U/mL IFNγ treatment, 10U/mL IFNγ 
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Figure S2. Autophagy CRISPR library screen design. 
(A) BV2-Cas9 cells transduced with the Autophagy CRISPR library were collected for 
the following conditions: five days post puromycin selection, mock treatment, 1U/mL 
Nγ ea e , 10  Nγ ea e   1  Nγ ea e   N CW3. 
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Tables  
Table 1. NGS validation data. Related to Figure 1,3,4,5. List of sgRNA sequences used 
in this report and validation of editing efficiencies by NGS. 
Table 2. Autophagy CRISPR library. Related to Figure 2. Annotation of sgRNAs and 
associated mouse genes in the autophagy CRISPR library.  
Table 3. Genes enriched and depleted for passage of BV-2 cells results. Related to 
Figure 2. Average LFC and STARS analysis for the CRISPR screen. 
Table 4. Genes depleted during passage of BV-2 cells compared to Project Achilles. 
Related to Figure 2. Candidate essential genes with FDR < 0.1 compared to Achilles 
Project annotations. 
Table 5. Genes enriched and depleted in 1U/mL or 10U/mL IFNγ treated cells. 
Related to Figure 2. Average LFC and STARS analysis for the CRISPR screen. 
Table 6. Genes enriched and depleted in 1U/mL IFN + MNoVCW3 infected cells. 
Results related to Figure 3. Average LFC and STARS analysis for the CRISPR  screen. 
Table 7. Supplemental cDNA sequences. Related to Methods. cDNA sequences for 
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The identification, targeting and restriction of replication niches of diverse intracellular 
pathogens via the cell intrinsic effects of interferon-γ (IFNγ)-induction is a critical innate 
immune process with significant physiologic importance. Norovirus is an intracellular viral 
pathogen that establishes replication complexes from secretory pathway and 
endoplasmic reticulum (ER)-derived membranous compartments (1). In IFNγ-induced 
cells a series of autophagy Genes (ATG genes) in combination with dynamin superfamily 
of large GTPases guanylate binding proteins (GBPs) and Immunity Related Guanosine 
Triphosphatases (IRGs) act in concert to restrict the formation of the norovirus replication 
complex (2, 3). The mechanism by which norovirus replication complexes are identified 
by the cell for restriction remains unknown. By utilizing genome wide CRISPR Cas9 
knock-out screens, we identified 51 candidate genes that are required for IFNγ-induced 
inhibition of norovirus replication. We validated that Cul3, Commd6, Cenpr1, and Stk24 
are required for IFNγ-induced inhibition of norovirus replication. We also confirmed that 
Klhl9 is the cullin-ring-ligase (CRL) substrate adaptor for Cul3 in this immune mechanism. 
Finally, we demonstrate that CUL3, KLHL9, Ubiquitin and GBPs localize to the murine 
norovirus replication complex in infected BV-2 cells. These studies elucidate a novel set 






IFNγ is a critical mediator of cell-intrinsic immunity to infectious diseases (4).  IFNγ inhibits 
murine norovirus (herein norovirus) replication by disrupting the formation and/or function 
of the membranous replication compartment upon which viral RNA synthesis occurs (2, 
3, 5–11). IFNγ-induced inhibition of intracellular replication of norovirus requires a series 
of ATG genes Atg7, Atg5, Atg16l1, Atg12, Atg3, Wipi2 and Gabarapl2 (2, 3, 5–12). 
Similarly, components of the IFNγ pathway and products of its program are also require 
for IFNγ-induced inhibition of norovirus (22,23-25). For example, Stat1 and Irf1 encode 
transcription factors essential for IFNγ responses (13), and are required for robust IFNγ-
induced inhibition of norovirus replication both in vitro in primary macrophages and in vivo 
(14–16).  
GBPs and IRGs proteins are interferon-stimulate-genes (ISGs) both required for inhibiting 
norovirus replication (3). In IFNγ-induced cells, GBPs and IRGs are found localized to the 
membranous intracellular compartment where norovirus establishes the replication 
complex (3). Loss of specific ATG genes prevents GBPs and IRGs from successfully 
targeting norovirus replication complexes (3). Similarly, loss of specific ATG genes 
prevents ubiquitin and GBPs from targeting the intracellular replication niche of 
Toxoplasma gondii (the parasitophorous vacuole) and bacteria (5, 6, 8, 10, 11, 17). In this 
infection context, ubiquitin systems serve to mark pathogen containing vacuoles as 
targets for GBPs and eventual restriction or destruction (6, 8, 11, 18). It is unknown if 
ubiquitin systems plays a critical role in identifying the replication niche of norovirus in the 
context of IFNγ-induced targeting of GBPs or IRGs.    
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Leveraging CRISPR screens, we identify a functional landscape of IFNγ-induced biology 
across multiple phenotypes in BV-2 cells with the specific goal of identifying host factors 
that are required for IFNγ-induced inhibition of norovirus replication. Ultimately, we 
classified 51 unique candidate genes required for IFNγ-induced inhibition of norovirus in 
BV-2 cells. We identified known host-factors required for this biology: Irf1 and Gabarapl2 
(herein Gate-16) (12, 16). We validated the role of the cullin-ring-ligase (CRL) Cul3 
(Figure 5A, 5B). We also saw significant enrichment of genes known to influence Cul3 
function, namely Senp8, Commd1, Commd2 and Commd6; and validated a functional 
role for Commd6 (Fig. 5A). We identified that Klhl9 is the substrate adaptor for Cul3 in 
IFNγ-induced inhibition of norovirus replication. Finally, we demonstrate that Cul3, Klhl9, 
ubiquitin and GBPs all localize to replication complexes containing the norovirus 
protease-polymerase (Pro-pol) protein in BV-2 cells (Fig. 6D). These findings reveal a 
novel critical mechanistic requirement of ubiquitin deposition at the membranous derived 






To better understand the mechanisms whereby IFNγ-induction influences BV-2 biology 
we employed a previously described CRISPR knock-out screening strategy (12) where 
we assessed the effects of each perturbation in our in vitro system. The major difference 
with this work is that we employed a genome wide library of guides targeting mouse genes 
(19)versus an autophagy focused CRISPR library. We designed multiple arms of our 
phenotypic screen to control for and assess overlapping biology (Supp. Fig. 1A). We 
conducted each arm of our screens at a representation of 2000 guides per gene to 
improve our ability to interpret negative selection results (12, 20). We used both a 
negative bionomial analysis and a guide level ranking algorithm (STARS) (19) to 
determine candidates and employed a STARS score FDR < 0.1 cutoff for consideration. 
We did not consider guides that mapped to multiple genes for this work. 
 
Identification of genes required for survival or improved growth in BV-2 cells 
during passage 
 
Passage of cells containing a CRISPR library is a form of selective pressure(21). Cells 
containing guides carrying insertions and deletions (indels) via Cas9 non-homologous 
end joining (NHEJ) at the site of essential genes should be depleted from a CRISPR 
library population over time (21). Alternatively, cells containing guides carrying indels in 
genes that are enriched over time should confer a pro-survival effect (21). To determine 
which genes are essential or pro-survival over a representative experimental window for 
our screening conditions, we harvested a representative sample of our CRISPR library 
five days post puromycin selection and compared this to a 48 hour mock treated sample 
(Supp. Fig. 1A).  
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Under these conditions, we observed guides for 1357 candidate essential genes with 
depleted guides under these conditions (Fig. 1A) and enrichment of guides for 34 
candidate pro-survival genes in BV-2 cells (Fig. 1A). Our data suggest that 6.8% of the 
~20,000 mouse genes in BV-2 cells are essential, this is consistent with estimates in other 
cell types using similar approaches (22, 23). Gene set enrichment analysis (GSEA) for 
our candidate essential genes identified 379 significantly enriched Reactome, Kegg and 
Gene ontology (GO) categories (FDR q-value < 0.05) (Table 3). Significantly enriched 
terms for essential genes included classes related to translation, the ribosome, RNA 
processing and the mitochondria, comprising categories previously characterized as 
essential across most cell types (Fig.1C and Table 3) (22–24). Of the 52 essential genes 
previously identified in BV-2 cells 42 (~81%) appeared to be essential under these 
conditions (12). We generated a network of protein-protein interactions (PPI) based on 
the essential and pro-survival genes and observed robust PPI enrichment (p-value <1.0-
16) (Fig. 8).   
We assessed if the gene effect among our essential BV-2 genes was concordant with 
results from existing gene dependency data from the Achilles Dependency Portal (25). 
The Achilles Dependency Portal assesses gene dependency using CRISPR based drop 
out screens in immortalized cell lines (25). All genes receive a CERES Gene Effect score 
to assess the magnitude of their gene dependency across many immortalized cell lines 
(25). A CERES score of 0 is equivalent to a non-essential gene while a score of -1 
corresponds to the median of all common essential genes (25). The mean CERES score 
for our BV-2 essential genes among 989 immortalized cell lines was -0.92 while the 
average CERES score for our pro-survival BV-2 genes among 989 cell lines was -0.02 
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(Fig. 1B). These data suggest that our essential genes in BV-2 cells are consistent with 
the negative gene effect seen across 989 immortalized cell lines.  
 
Interestingly, of the 34 candidate pro-survival genes identified in BV-2 cells many were 
core components of the type I interferon signaling pathway (Figs. 1A, 1D). Cells with 
guides targeting Ifnar1, Ifnar2, Irf9 and Jak1 had a fitness advantage in BV-2 cells under 
these conditions (Figs 1A, 1D). GSEA for our candidate pro-survival genes identified 121 
significantly enriched categories (FDR q-value < 0.05) among GO, Kegg and Reactome 
databases. Significantly enriched GO terms for pro-survival genes included classes 
related to G-protein coupled receptor activity, Jak Stat signaling and type I interferon (Fig. 
1D). A PPI network for the pro-survival BV-2 candidate genes recovered a significantly 
enriched network (p-value < 1.85 x 10-8) and GO term enrichment of Type I interferon 
signaling (FDR <0.008) (Fig. 1F). Type I interferon has been shown to promote 
inflammation in the context of microglia and Alzheimer’s disease(26), therefore loss of 
this pathway may promote a less inflamed environment for BV-2 cells during passage.  
 
In summary, for purposes of validation and interpretation, we used these findings to 
annotate the results of our parallel CRISPR screen conditions (Figs. 7, 2A, 3A and 4A). 
If a pro-survival gene was also enriched in a separate screening condition we annotated 
it accordingly and similarly for essential genes in other depletion conditions. 
 
Identification of genes playing a critical role in IFNγ-induced cell death in BV-2 cells  
 
High doses of IFNγ are sufficient to cause cell death in BV-2 cells (12, 27). To control for 
this, we designed two IFNγ-treatment screen conditions: treatment of BV-2 cells with 
1U/mL IFNγ for 40 hours and treatment of BV-2 cells with 10U/mL IFNγ for 40 hours (Fig. 
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7). We compared guides from 1U/mL IFNγ treated samples to mock treated samples and 
saw few significantly enriched or depleted guides (Figs. 2A and Table 2) suggesting that 
a dose of 1U/mL IFNγ in BV-2 cells under these conditions did not result in a robust 
selection pressure. We did observed enriched guides for Ifngr1 (Fig. 2A) confirming that 
loss of Ifngr1 is protective against IFNγ induced cell death in BV-2 cells (19). Ripk1 guides 
were significantly depleted under these conditions, confirming that loss of Ripk1 
sensitizes BV-2 cells to IFNγ-induced cell death (Fig. 2A) (27). 
Treatment of BV-2 cells with 10U/mL IFNγ for 40 hours resulted in robust enrichment and 
depletion of guides (Figs 2B and Table 3). After annotating for essential and pro-survival 
effects, we observed guides for 191 unique genes enriched and guides for 110 unique 
genes depleted under these conditions (Fig. 2B and Table 5). The top four unique genes 
with enriched guides in the 10U/mL IFNγ treatment condition constituted core 
components of IFNγ signaling pathway: Stat1, Ifngr2, Ifngr1 and Jak2 and previously 
identified as protective against IFNγ induced death in BV-2 cells (13, 19, 27). We also 
observed significant enrichment of guides targeting tumor necrosis factor receptor 1a 
(Tnfrsf1a) a component of the TNF-receptor superfamily (28) and important in IFNγ 
mediated death in BV-2 cells (27). GSEA identified significant enrichment in 182 Kegg, 
Reactome and GO categories (Table 3). Significantly enriched terms (FDR q-value <0.05) 
included translation, mitochondrial translation, Jak Stat signaling and IFNγ signaling, all 
previously implicated in IFNγ mediated immune responses (Fig. 2D) (13, 19). A network 
among unique enriched genes identified a significant enrichment in PPIs (p-value < 1.0 x 
10-16) (Fig. 2F).  We confirmed that Stat1-/- BV-2 cells had improved viability compared to 
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wild-type cells in a dose escalation of IFNγ treatment, validating that loss of STAT1 is 
protective from IFNγ-induced cell death in BV-2 cells (Fig 10).  
 
Treatment of BV-2 cells with 10U/mL IFNγ for 40 hours revealed robust depletion in 
guides targeting genes in the autophagy pathway, confirming previous observations (Fig. 
2B and E) (12, 27). Guides for Atg5, Atg9a, Atg12, Atg101, Atg14, Atg7, and Rb1cc1 
(also known as Fip200) were significantly depleted in the 10U/mL IFNγ treatment 
condition (Fig. 2B). Guides for the genes Gate-16, Irgm2, Atg10 and Atg3 were also 
significantly depleted but have not been previously described to play a role in IFNγ-
induced death in BV-2 cells (Fig. 2B). Gate-16 and Irgm2 were recently described to play 
a role in inflammasome activation in response to gram negative bacteria (29). Among the 
most depleted guides were Pigu, Pigk, Pigt, Pigs and Gpaa1 which compose the complex 
required for transamidation of glycosylphosphatidylinositol (GPI) anchors en bloc to 
nascent proteins (Fig. 2B) (30)To our knowledge the GPI transamidation complex has not 
been known to protect against IFNγ-induced cell death in BV-2 cells or in other contexts. 
GSEA analysis found significant enrichment of 308 Kegg, Reactome and GO categories 
(Figs 2C and Table 3). Among the significantly enriched terms were related to innate 
immune pathway regulation including TNF-signaling, Toll like receptor signaling, TNFR1 
induced Nf-kappaB signaling and the autophagy pathway (Fig. 2C) (Table 3). A network 
of the depleted genes revealed a significant enrichement of interactions (p-value 1.0 x 10-
16) (Fig. 2E). We used these findings to annotate the results of our 1U/mL IFNγ and 
MNoVCW3 CRISPR screen condition (Fig. 7) with 10U/mL IFNγ enriched and depleted 
designations to caveat the interpretation of their effect under similar conditions. 
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Genes playing a critical role in norovirus induced cytopathicity in BV-2 cells  
 
To better understand norovirus infection in untreated BV-2 cells we analyzed existing data 
utilizing similar methods to our screening approach (Fig. 7) (31) . In BV-2 cells surviving 
MNoVCW3 induced cytopathicity, we identified enrichment of guides targeting 327 unique 
genes (Fig. 3A) and 40 unique genes depleted among cells succumbing to MNoVCW3 
cytopathicity (Table 5). The most enriched guides targeted the murine norovirus receptor 
Cd300lf (32) (Fig. 3A). G3bp1, Kmt2d, Sptlc1, and Sptlc2 were also among the most 
enriched guides and also previously confirmed as essential for norovirus replication in 
BV-2 cells (31–33) (Fig. 3A). We also identified Mettl14 and Mettl3 to have significantly 
depleted guides under these screening conditions, as previously reported (Fig. 3A) (31) . 
Significantly enriched GSEA categories (FDR q-value < 0.05) for enriched genes included 
terms relevant to methyltransferase activity, chromatin, and ribosome biology (Figure 3B 
and Table 3).  
Among the most depleted guides under MNoVCW3 infection conditions targeted the 
lipopolysaccharide induced Tnf factor (Litaf) a transcription factor known to mediate 
inflammatory cytokine induction in macrophages (34). We also identified depleted guides 
for Ifitm2, a well described anti-viral immune mediator (35) (Fig. 3A). GSEA for genes with 
depleted guides identified significant category enrichment (FDR q-value <0.05) for 
mitochondrial processes and ubiquitin mediated proteolysis (Fig. 3C) (Table 5). Overall, 
we used these findings to annotate the results of the 1U/mL IFNγ and MNoVCW3 CRISPR 
screen condition (Figure 4A and 7) with MNoVCW3 enriched and depleted designations to 
caveat the interpretation of their effect under similar conditions.  
Identification of genes playing a critical role in regulating IFNγ-induced inhibition 
of norovirus replication 
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We aimed to identify candidate genes that regulate IFNγ-induced control of MNoVCW3. 
Therefore, we designed a condition of our CRISPR screen where cells were pretreated 
with 1U/mL of IFNγ and subsequently infected with MNoVCW3 (Figure 7). When compared 
to mock treatment samples we identified 165 unique genes with guides significantly 
enriched under these conditions (Fig. 4A)(Table 2). GSEA for enriched genes under these 
conditions revealed 30 categories with terms including sphingolipid biosynthesis, 
ceramide biosynthesis, promoter driven DNA binding and spliceosome complex (Fig. 4C). 
Among the identified genes were Uba5, previously shown to regulate IFNγ-induced 
control of MNoVCW3 replication (Fig. 4A) (36).  Network analysis of the enriched genes 
identified significant PPI enrichment (p value < 6.64 x 10-8) (Fig. 4E). We observed 
significant enrichment of Usp18, a known negative regulator of type I interferon (Figure 
4A and 4E) (37). We also observed significant enrichment of Tabbp (also known as 
Tapasin), H2-Q1 and H2-D1, all members of the major histocompatibility complex class I 
processing machinery (Fig. 4E) (38). Guides targeting Otud5 and Traf3 were also 
significantly enriched, Otud5 deubiquitinates Traf3 and subsequently suppresses the type 
I interferon response via ubiquitination of Traf3 (39). These data support our approach to 
identify candidate genes that regulate IFNγ-induced control of MNoVCW3.   
       
Identification of genes playing a critical role in IFNγ-induced inhibition of norovirus 
replication 
 
To identify candidate genes that are required for IFNγ-induced control of MNoVCW3 we 
compared the condition of BV-2 cells receiving 18 hours of pretreatment with 1U/mL IFNγ 
+ MNoVCW3 infection to mock treatment cells (Figure 7). We identified significant depletion 
of guides targeting 51 unique genes under these conditions (Fig. 4A, Table 5). Among 
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the identified genes, we saw an enrichment of genes with a confirmed role for IFNγ-
induced control of MNoVCW3. Cul3 was previously identified using a similar approach in 
BV-2 cells (12). We also identified Irf1, a downstream transcription factor of the IFNγ 
response and previously shown to be required for control of MNoVCW3 (12, 16). Gate-16 
was significantly depleted in both the IFNγ + MNoVCW3 and the 10U/mL IFNy condition, 
suggesting it may play a role in both control of MNoVCW3 and IFNγ-induced cell death. 
We saw enrichment of Atg9a under these conditions but not to a level of significance 
meeting our criteria for consideration (Table 2). The genome wide mouse CRISPR library 
(19) does not contain guides targeting Wipi2 (Table 7). GSEA enrichment analysis of our 
unique identified 16 enriched pathways unique to the IFNγ + MNOVCW3 infection 
condition. A network generated from the unique depleted genes demonstrated significant 
PPI enrichment (p value 1 x 10-8) and identified enrichment for the GO term pertaining to 
positive regulation of protein ubiquitination (Figure 4D).  
 
We proceeded to validate a subset of candidate genes that were unique to the 1U/mL 
IFNγ and MNoVCW3 condition. We chose to validate the unique genes most enriched in 
the IFNγ and MNoVCW3 depleted condition: Cnep1r1, Commd6, Cul3 and Stk24 (Fig. 5A 
and Table 5). We included Gate-16 as a positive control due to it’s previously described 
role in IFNγ-induced inhibition of MNoVCW3 (Fig. 5A) (3). We generated heterogenous 
knock-outs in BV-2-Cas9 cells for these candidate genes based on the two highest 
ranking guides from the screen results (Table 5) and confirmed a high percentage of indel 
frequency compared to non-targeting controls at the predicted genomic site of guide 
editing (Table 6). In a viability assay, all of the heterogenous knock-out cells were unable 
to inhibit MNoVCW3 induced cytopathicity when treated with IFNγ compared to non-
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targeting control cells (Fig. 5A). To further assess the requirement of Cul3 under these 
conditions, we generated Cul3-/- BV-2 cells (Table 6) and confirmed by plaque assay that 
Cul3-/- was unable to inhibit MNoVCW3 after treatment with IFNγ (Fig. 5B). Together, these 
data support the validity of our approach and confirm the requirement of CUL3 for IFNγ-
induced inhibition of MNoVCW3 in BV-2 cells. 
 
Klhl9 is required for IFNγ-induced inhibition of norovirus  
 
Cullin-ring-ligase (CRL) complexes containing the E3-ligase CUL3 ubiquitinate their 
target substrates via adaptor proteins (40). Adaptor proteins bind CUL3 in complex via 
either kelch-domains (KLHL) or brica/brac/tram/trac domains (BTB). We did not observe 
any KLHL- or BTB- proteins among our IFNγ + MNoVCW3 depleted candidate genes that 
met our strict criteria for consideration (Table 5). We relaxed our criteria for candidate 
consideration and assessed all IFNγ + MNoVCW3 compared to the mock treatment 
condition for KLHL- and BTB- domain containing proteins (Fig. 6A). The only candidate 
KLHL- / BTB- gene that approached significant depletion in the IFNγ + MNoVCW3 condition 
was Klhl9 (Fig. 6A). We generated a pool of heterogenous knock-out BV-2 cells targeting 
Klhl9 and confirmed a high percentage of indel frequency compared to a non-targeting 
control (Fig. 6B). In a viability assay, Klhl9 heterogenous knock-out cells were unable to 
inhibit MNoVCW3 induced cytopathicity when treated with IFNγ compared to non-targeting 
control cells (Fig. 6C).  
CUL3, KLHL9 and KLHL13 are required for correct chromosome alignment in metaphase, 
proper midzone and midbody formation, and completion of cytokinesis, at the centromere 
spindle complex (41) . KLHL9 and KLHL13 are also required for limiting intracellular 
replication of Salmonella enterica in HeLa cells (42) . To confirm if KLHL13 is also 
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required for IFNγ-induced inhibition of MNoVCW3 we generated Klhl13-/- cells (Table 6). In 
a plaque assay, Klhl13-/- cells significantly controlled MNoVCW3 replication upon IFNγ 
treatment compared to WT cells (Fig. 6D). Additional KLHL proteins have a demonstrated 
role in infection, inflammation, and innate immunity: KLHL19 (herein KEAP1) plays a role 
in inflammation and the type I interferon responses (43) ; KLHL20 is a negative regulator 
of death-associated protein kinase (DAPK) and interferon induced cell death via CUL3 
ubiquitination (44); KLHL22 and CUL3 ubiquitinate DEPDC5 resulting in the inhibition of 
autophagy induction(45). To test the requirement of other relevant KLHL proteins for 
IFNγ-induced control of MNoVCW3 we generated Keap1-/-, Klhl20-/- and Klhl22-/- BV-2 cells 
(Table 6). In a plaque assay, Keap1-/-, Klhl20-/- and Klhl22-/- BV-2 cells inhibited MNoVCW3 
replication upon IFNγ treatment as well as WT cells (Fig. 6D).  
Finally, to gain a better understanding of the role CUL3 and KLHL9 may play in IFNγ and 
norovirus biology we conducted immunofluorescence microscopy on WT BV-2 cells 
infected with MNoVCW3 (Fig. 6E). We observed that CUL3 localized to norovirus 
replication complexes containing Pro-pol in norovirus infected BV-2 cells (Fig. 6E) as did 
GBPs (Fig. 6E). KLHL9 also localized to norovirus replication complexes containing Pro-
pol (Fig. 6E). Ubiquitin was observed localized to CUL3 and Pro-pol containing norovirus 
replication complexes (Fig. 6E). Overall, these data suggest that CUL3 and the substrate 
adaptor KLHL9 are required for IFNγ-induced inhibition of MNoVCW3 replication in BV-2 
cells. Furthermore, the function of these newly identified proteins may be executed at the 






Assessing complex biology with CRISPR screens  
 
In this work, utilizing CRISPR Cas9 knock-out screens, we identified genes underlying 
cell intrinsic phenotypes in BV-2 cells. Our primary goal was to uncover host factors 
required for IFNγ-induced inhibition of norovirus. We used viability of BV-2 cells as the 
phenotypic endpoint for our approach. Due to the complexity of our phenotypic question 
we assumed that we would need rigorous controls to properly interpret our results (Figure 
7). Therefore, we designed a screen condition for each potential selective pressure 
influencing our biological system (Figure 7). Our results demonstrate a comprehensive 
understanding of the basic biology underlying BV-2 cells, the IFNγ response and the 
IFNγ-induced inhibition or norovirus. 
 
We assessed what genes would influence basic growth of BV-2 cells in tissue culture 
(Figure 1A ,8 and Table 2). As expected, some of the genes identified as essential in BV-
2 cells appeared in additional depletion conditions (Figure 2A, 3A, 4A Table 5). 
Interestingly, not all essential genes appeared in every depletion condition but rather only 
a subset (Table 5). This suggests, for example, that the 31 depleted genes annotated in 
the 10u/mL IFNγ-induced cell death condition as essential, may in fact play an important 
role in protecting cells from IFNγ-induced death. However, any attempt to experimentally 
interrogate these candidate genes could be problematic if we expect loss of these genes 
to result in a baseline decrease in viability. The same paradigm would hold for BV-2 genes 
identified as pro-survival in orthogonal screening conditions (Figure 2A, 3A, 4A and 
Table5). In this scenario, guides targeting a gene that causes a baseline increase in cell 
viability could also bias the interpretation of a result. More nuanced or less penetrant 
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validation techniques will be required to confirm these observed functional overlaps for 
the results presented here.    
 
Novel outcomes observed in IFNγ-induced cell death in BV-2 cells  
 
The effects of IFNγ-induction, specifically IFNγ-induced cell death is well described 
selective pressure in BV-2 cells (12, 19, 27), therefore, designing a condition controlling 
for this biology was critical (Figure 7). As expected, we failed to see robust enrichment or 
depletion of guides in BV-2 cells treated with a sub-lethal dose of 1U/mL of IFNγ in BV-2 
cells (Figure 2A). Escalation of the IFNγ dose to 10U/mL resulted in the robust 
identification of genes. We recapitulated the observation that the host components 
underlying IFNγ-induced death in BV-2 cells appeared to be distinct from IFNγ-induced 
control of norovirus (Figure 2B, 4A, Table 5) (12, 27). A network containing all genes from 
the 10U/mL IFNγ-induced death condition revealed a significantly enriched PPI network 
(p-value < 1.0 x 10-16) with overlap between enriched and depleted results (Figure 9), 
suggesting a functional link between the two. This will require validation and further 
studies to better understand how these genes integrate with our current understanding of 
IFNγ biology.      
 
Novel outcomes observed in MNOVCW3 induced cytopathicity  
 
The biology of norovirus induced cytopathicity in BV-2 cells has been previously 
described (31, 32). A network generated from all of the results of this condition revealed 
significancy enriched (p value 1 x 10-16) PPIs (Figure 10) pertaining to cellular processes 
co-opted by the norovirus replication program, the largest such cluster contains genes of 
the ribosome large subunit (Figure 10). Depleted genes form a clear network with the 
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enriched genes, as in the 10U/mL IFNγ-induced cell death condition (Figure 9). Again 
suggesting that the depleted and enriched results from these functional genomics screens 
are related. Future studies will be needed to verify a functional role of these candidate 
innate-immune genes.   
 
Novel outcomes in IFNγ-induced inhibition of norovirus 
 
In this work we identified at least 51 novel host-factors required for IFNγ-induced inhibition 
of norovirus induced cytopathictiy in BV-2 cells (Fig. 4A and Table 5). If we assume that 
the annotated functional overlaps with the essential, IFNγ treatment, and norovirus 
infection conditions also contribute to IFNγ-induced inhibition of norovirus then the 
number of identified host factors may in fact be 121 (Table 5). For the functional overlap 
between IFNγ-induced cell death and IFNγ-induced inhibition of norovirus this is entirely 
plausible. We previously identified that Wipi2 contributed to both IFNγ-induced cell death 
and IFNγ-induced inhibition of norovirus and T. gondii (12); Atg5, Atg12, Atg16l1 are also 
examples of this overlap (12, 27). Therefore, functional overlaps derived from the results 
of essential genes and those depleted in norovirus infected cells alone may in fact also 
contribute to IFNγ-induced control of norovirus but this will require formal validation.   
 
CUL3 and KLHL9 target norovirus replication complexes with ubiquitin  
 
CUL3 and KLHL9 were confirmed as novel components required for IFNγ-induced 
inhibition of norovirus replication in BV-2 cells (Figs. 5B, 6C). CUL3 and KLHL9 were also 
observed to be localized to the replication complex in norovirus infected BV-2 cells (Fig. 
6E). Under the same conditions we observed localization of GBPs and ubiquitin (Fig. 6E). 
We did not find a functional role for any additional CRL substrate adaptor proteins 
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previously described to play a role in innate-immunity, autophagy or the IFNγ response 
(Fig. 6D). These findings suggest there is a specificity among CRL family members and 
the KLHL substrate adaptor family with respect to the IFNγ-induced inhibition of norovirus. 
Future studies will need to undertake identifying what components of the norovirus 
replication complex are targeted by this ubiquitin ligase complex and if they are host or 
viral proteins.     
 
Integrating novels findings with existing paradigms 
 
These observations prompt obvious mechanistic questions given our current 
understanding of IFNγ-induced inhibition of norovirus (2, 3, 12, 16, 46, 47). In the spatio-
temporal hierarchy of this innate immune process, there are likely three critical events for 
effective control of norovirus: 1) IFNγ induction alters the landscape of the cell; 2) 
norovirus replication complex is identified; 3) norovirus replication complex is restricted 
or eliminated by GBPs and or IRGs. We believe our findings integrate with and improve 
our understanding of this existing paradigm: 1) IFNγ-induction alters the landscape of the 
cell: Irf1, is the critical transcription factor required for induction of immune effector 
proteins, namely IRGs and GBPs and likely other critical proteins (16); 2) norovirus 
replication complex is identified and targeted: how specifically, the norovirus replication 
complex is identified remains unknown, however in this step, CUL3 and KLHL9 may be 
sufficient to ubiquitinate host or viral components of the replication complex (Figure 6D); 
3) norovirus replication complex is eliminated by immune GTPases: ubiquitin designates 
what vacuoles are targeted by IRGs and GBPs in bacterial and T. gondii infection (18) 
and this identification step may be the case for norovirus as well. This work sheds light 
on on a minor but critical step of IFNγ-induced inhibition of norovirus.  
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Materials and Methods 
 
Cells 
BV-2 and HEK293T cells were cultured in Dulbecco’s Modified Eagle Medium (DMEM, 
Gibco) with 10% fetal bovine serum (FBS) and 1% HEPES. BV-2 Cas9 cell lines were 
generated using standard protocols (12, 32). Cul3-/-, Klhl13-/- , Keap1-/-, Klhl20-/- and 
Klhl22-/-  cells were generated by introducing Cas9 and gRNAs into BV2 by nucleofection. 
For selection, 5 μg/mL puromycin (Thermofisher) and 5 μg/mL blasticidin (Thermofisher) 
was added to BV-2 cells. 
BV-2 mutant cell lines were generated at the Genome Engineering and iPSC center at 
Washington University School of Medicine (32). sgRNAs (Table S1) were nucleofected 
with Cas9 into wild type BV2 cells and clones were screened for indels by sequencing the 
target region with Illumina MiSeq at approximately 500x coverage. Indel signature 
frequency was determined using an in-house algorithm (GEiC, Washington University 
School of Medicine, St. Louis, MO). 
Viruses and viral assays 
MNoVCW3 (Gen bank accession no. EF014462.1) was generated by transfecting a 
molecular clone (48) into HEK293T cells (P0 stock), which was passaged on BV-2 cells. 
After two passages, infected cells were frozen at -80C and thawed, cleared of cellular 
debris and virus was concentrated by tangential flow filtration. For infection, WT or 
knockout BV-2 cells were seeded at 104 cells/well of a 96-well plate. After 8 hours, cells 
were treated with 1U/mL of IFNγ (BioLegend). 16 hours later MNoVCW3 was added at an 
MOI 5.0. Infected cells were harvested at 24 hpi and frozen at -80°C prior to plaque assay. 
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For cell viability CellTiter-Glo reagent (Promega) was added to wells of a 96-well plate, 
incubated for 10 minutes at room temperature and then cellular ATP content was 
measured.  Viral titers were determined in triplicate by plaque assay on BV-2 cells. BV-2 
cells were seeded at 2 x 106 cells/well of a six-well plate and 24 hours later 100uL of 10-
fold serially diluted samples were applied to each well for 1 hour with orbital rocking at 
room temperature. Viral inoculum was aspirated, and 2 ml of warmed MEM containing 
10% FBS, 2mM L-Gluatmine, 10 mM HEPES, and 1% methylcellulose was added. Plates 
were incubated for 48 hours prior to visualization after staining with 0.2% crystal violet in 
20% ethanol. 
 
Immunofluorescence microscopy  
Cells seeded on glass coverslips (Thermofisher) in 24-well plates (Corning) were fixed in 
4% PFA in PBS, permeabilized with 0.25% Triton X100 and blocked with 1% BSA and 
stained with anti-Cul3 (Bethyl Laboratories), anti-Klhl9/Klhl13 (Santa Cruz 
Biotechnology), anti-Gbp1-5 (Santa Cruz Biotechnologies), anti-Ubiquitin (Cell Signaling 
Technologies) or Pro-pol (3) . 
 
CRISPR-Cas9 genome wide library generation and screen  
3.2x108 BV-2-Cas9 cells (27, 32, 36) were transduced with a lentivirus stock (transduction 
efficiency 50%) resulting in 1.6 x108 cells. 36 hours later puromycin was added and 
transduced cells selected for five days. Five days post puromycin selection 1.6x108 cells 
were harvested and DNA isolated for sequencing (QIAamp DNA Blood Midi Kit, Qiagen). 
For each experimental condition (mock, 1U/mL IFNγ, 10U/mL IFNγ and 1U/mL IFNγ + 
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MNoVCW3) 1.0x107 cells were seeded in 16 15cm2 dish. Eight hours later, cells were 
treated with media, 1 U/ml IFNγ or 10U/mL IFNγ. After 16 hours cells were either mock 
infected or infected with MNoVCW3 at an MOI of 5.0. Cells were harvested 24 hour later 
for isolation of DNA for sequencing and assessment of cell viability (Trypan blue 
exclusion). Genomic DNA was sequenced and analyzed (27, 32, 36). Volcano plots were 
generated using the hypergeometric distribution method 
(https://github.com/mhegde/volcano_plots) and screen results were analyzed using 
STARS analysis (https://portals.broadinstitute.org/gpp/public/software/stars). 
 
Quantification and Statistical Analysis 
Data were analyzed with Prism 7 software (GraphPad Software, San Diego, CA). Volcano 
plots were generated using R-studio (Integrated Development for R. RStudio, PBC, 
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Figure 1: Identification of genes required for viability in passaged BV-2 cells. (A) 
Volcano plot of mock treatment guides enriched or depleted relative to five days post 
puromycin selection. (B) Density plot of Gene effect (CERES score) for essential BV-2 
genes and pro-survival BV-2 genes. (C) and (D) top 10 GSEA pathways (FDR q-val 
<0.05) enriched in either essential or pro-survival results based on 10% of all ranked 
guides generated by STARS. (E) Network of protein-protein interactions (PPIs) identified 
Mean CERES Score
BV-2 Pro-survival = -0.02
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in the pro-survival condition in BV-2 cells. Functionally related clusters are grouped and 
annotated accordingly. The network was generated using cytoscape version 3.8.2 
(Shannon et al., 2003). Interactions were generated from String DB version 11 
(Szklarczyk et al., 2019) protein query for Mus musculus with a confidence cutoff of 0.7, 
singletons were not included for visualization. In (A), volcano plot is the average log2 fold 
change (LFC) of all sgRNAs for each gene plotted against the –log10(p-value) for each 
gene. In (A), gold and purple points indicate a STARS score FDR < 0.1; light grey points 
represent genes targeted with guides but showing no significant enrichment or depletion; 
dark grey points represent non-targeting guides; select genes with STARS score FDR < 




Figure 2: Identification of genes required for viability in IFNγ-treated BV-2 cells. (A) 
Volcano plot of guides enriched or depleted after 1U/mL IFNγ treatment relative to mock 
treatment. (B) as in (A) for 10U/mL IFNγ treatment. (C) and (D) top 10 GSEA pathways 
enriched in 10U/mL IFNγ treatment enrichment or depletion results in BV-2 cells as in 
Figure 1B and 1C. € and (F) PPI networks identified fromin the 10U/mL IFNγ depleted or 
enriched condition in BV-2 cells as in Figure 1D, with essential and pro-survival genes 















-log10 (FDR  q-value)











-log10 (FDR  q-value)












indicate STARS score FDR< 0.1. In (A), wheat points indicate unique genes depleted with 
1U/mL IFNγ treatment; tan points indicate unique genes enriched upon 1U/mL IFNγ 
treatment; (B) is same as (A) with 10U/mL IFNγ treatment; gold and purple labeled points 
indicate essential and pro-survival genes; light grey points represent genes targeted with 
guides but showing no significant enrichment or depletion; dark grey points represent 






Figure 3. Analysis of genes required for MNoVCW3 cytopathicity in BV-2 cells. (A) 
Volcano plot of guides enriched or depleted after MNoVCW3 infection relative to mock 
treatment.  (B) and (C) top 10 GSEA pathways enriched in MNoVCW3 infection enrichment 
or depletion results in BV-2 cells (FDR q-val <0.05). In (A), dark sea green points indicate 
unique genes depleted with MNoVCW3 infection; dark green points indicate unique genes 
enriched upon MNoVCW3 infection; gold and purple labeled points indicate essential and 
pro-survival genes; light grey points represent genes targeted with guides but showing no 
significant enrichment or depletion; dark grey points represent non-targeting guides; 
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Figure 4: Identification of genes required for IFNγ-
induced norovirus cytopathicity in BV-2 cells. (A) Volcano plot of guides enriched or 
depleted after 1U/mL IFNγ + MNoVCW3 infection relative to mock treatment. (B) and 
(C) top 10 GSEA pathways enriched in 1U/mL IFNγ + MNoVCW3 infection enrichment or 
depletion results (FDR q-val <0.05). All red, blue, tan, wheat, dark green, dark sea green, 
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1U/mL IFN + MNoVCW3 unique depleted or enriched genes, PPI network was generated 
as in Figure 1E.  In (A), red points indicate unique genes depleted with 1U/mL IFNγ + 
MNoVCW3 infection; blue points indicate unique genes enriched upon 1U/mL IFNγ + 
infection; dark green and dark sea green points indicate enriched and depleted MNoVCW3 
genes; tan and wheat points indicate enriched and depleted 10U/ml IFNγ genes; gold and 
purple points indicate essential and pro-survival genes; light grey points represent genes 
targeted with guides but showing no significant enrichment or depletion; dark grey points 





Figure 5: Validation of genes required for IFNγ-induced norovirus cytopathicity in 
BV-2 cells. (A) Viability assay of 1U/mL IFNγ + MNoVCW3 infected Cas9-BV-2 cells 
expressing either NT, Cnep1r1, Commd6, Cul3, Gabarapl2 or Stk24 targeting guide. (B) 
Plaque assay of WT or Cul3-/- 1U/mL IFNγ + MNoVCW3 infected BV-2 cells. Values in (A),  
and (B) represent means  ± SEM from two independent experiments. P value ≤ 0.0001 
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determined by 2-way ANOVA with Tukey’s multiple comparison test, in (B) P value 





Figure 6: Klhl9 is required for IFNγ-induced inhibition of norovirus cytopathicity in 
BV-2 cells. (A) volcano plot as in Figure 4A with all Klhl and Btb genes labeled. (B) 
Targeted deep sequencing indel frequency results of NT or Klhl9 guide expressing Cas9-
BV-2 cell. (C) Viability assay of 1U/mL IFNγ + MNoVCW3 infected Cas9-BV-2 cells 
expressing either a NT or Klhl9 specific guide. (D) Plaque assay of 1U/mL IFNγ + 
MNoVCW3 infected WT, Klhl13-/-, Keap1-/-, Klhl20-/-, and Klhl22-/- BV-2 cells. (F) 
Immunofluorescence assay of WT BV-2 cells infected with MNoVCW3 for 12 hours. 
Values in (C) (D) represent means ± SEM from two to three independent experiments. 
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Images in (E) are representative of three independent experiments. P value ≤ 0.0001 
(****) were considered statistically significant. ns, not significant. In (C) and (D) P value 






Figure 7. Genome wide CRISPR screen design. (A) Cas9-BV-2 cells transduced with 
a genome-wide CRISPR guide library targeting mouse genes (Doench et al., 2016) were 
collected under the following conditions: five days post puromycin selection, 
mock treatment, 1U/mL IFNγ treatment, 10U/mL IFNγ treatment, MNoVCW3 infection and 
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Figure 8. PPI network for essential and pro-survival conditions in BV-2 cells. (A) 
PPI network for essential and pro-survival genes identified from comparing day 5 post 
puromycin selection condition to mock treatment condition with STARS score ranking 








Figure 9. PPI network for 10U/mL IFNγ enriched and depleted genes in BV-2 cells. 
(A) PPI network for all enriched and depleted genes identified in the 10U/mL IFNγ 
treatment compared to mock treatment condition with STARS score ranking FDR <0.1. 
Essential and pro-survival annotated genes omitted (Table S5). PPI network was 




10U/mL IFNg Enriched genes















Figure 10. Stat1-/- BV-2 cells are resistant to IFNγ-induced cell death. (A) Viability 
assay of 1U/mL, 10U/mL or 100U/mL IFNγ treatment for 40 hours in WT BV-2 cells or 
Stat1-/- cells. Values in (A) represent means ± SEM from two independent 
experiments. P value ≤ 0.0001 (****) were considered statistically significant. ns, not 
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Figure 11. PPI network for enriched and depleted genes from MNoVCW3 induced 
cytopathicity in BV-2 cells. (A) PPI network for all enriched and depleted genes 
identified in MNOVCW3 induced cytopathicity compared to mock treatment condition with 
STARS score ranking FDR <0.1. Essential and pro-survival annotated genes omitted 















Figure 12. PPI network for enriched and depleted genes from 1U/mL IFNγ + 
MNoVCW3 induced cytopathicity in BV-2 cells. (A) PPI network for all enriched and 
depleted genes identified in 1U/mL IFNγ + MNOVCW3 induced cytopathicity compared to 
mock treatment condition with STARS score ranking FDR <0.1. Essential and pro-survival 
annotated genes omitted (Table S5). PPI network was generated as in Figure 1E.     
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Table 1. Hypergeometric analysis for all conditions. Related to Figures 1, 2, 3, 4. 
Average LFC and FDR scores for all sgRNAs in each CRISPR screen condition. 
Table 2. STARS analysis for all conditions. STARS analysis for the each CRISPR 
screen condition. 
Table 3. GSEA for all conditions. Related to Figures 1, 2, 3, 4. Positive and negative 
GSEA enrichment tables for the top 10% of ranked sgRNAs by STARS analysis for each 
CRISPR screen condition. 
Table 4. Achilles Dependency Map CERES gene effect scores. Related to Figure 1. 
CERES Gene Effect scores download from Achilles Project for all candidate essential and 
pro-survival BV-2 genes with STARS score FDR < 0.1 compared to Achilles Project 
annotations. 
Table 5. Functional overlap between CRISPR screen conditions. STARS scores with 
FDR<0.1 annotated for function gene overlaps between different CRISPR screen 
conditions.  
Table 6. NGS data for all BV-2 knock-out cells. Related to Figures 5, 6. List of sgRNA 
sequences used in this report and validation of editing efficiencies by NGS. 
Table 7. Genome wide mouse CRISPR library. Related to Figures 1, 2, 3, 4. Annotation 
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Summary of results 
 
Data presented here, and significant prior work, demonstrate the existence and 
physiological importance of a unique IFNγ-induced ATG gene-dependent process 
responsible for creation of a cellular environment that is hostile to the replication of 
phylogenetically distinct pathogens. This mechanism appears programmable with the 
participation of a core machinery including WIPI2B, ATG9A, ATG7, ATG5-12-16L1, ATG3 
and ATG8 family members rendered pathogen-specific by proteins such as P62 and 
IFNγ-induced GTPases (1–3). These new data further support the conclusion that 
cassettes of ATG genes have been leveraged by the immune system to perform cytokine-
induced tasks that block replication and clear pathogens as previously proposed (3–5). 
This system is programmable via the involvement of a variety of other gene products and 
focuses on altered intracellular membranes created as diverse pathogens hijack and 
evade normal cellular functions. 
Furthermore, using an unbiased approach, we introduce a significant number of novel 
genes that are also responsible for rendering norovirus ineffective in the context of IFNγ 
and myeloid cells. Several of these genes already have established functions in IFNγ-
dependent immunity, including IRF1 and GATE16 (1, 6, 7). CUL3 and KLHL9 appear to 
be functionally required for IFNγ-dependent immunity and found at the norovirus 
replication complex in concert with ubiquitin and GBPs. These new findings support the 
conclusion that norovirus along with parasites and bacteria utilize ubiquitin as a mediator 
to link the intracellular replication niches of pathogens with products of IFNγ-induction.  
 





Several key questions arise from the conclusions of this work. First, do these findings 
continue to be as robust in in vivo models of infection? To our knowledge Wipi2-/- or Wipi2 
conditional mice do not currently exist. Conditional Cul3fl/fl mice are available to the 
research community (8) therefore, testing the requirement of CUL3 in robust models of 
infection and IFNγ will be critical to our understanding of this biology. Second, what is the 
role of PtInds in IFNγ and ATG gene dependent immunity? Wipi2-/- BV-2 cells 
complemented in trans with domains defective in binding PtdIns do not rescue IFNγ-
induce inhibition of norovirus in BV-2 cells. The yeast homolog of WIPI2 (Svp1p) has a 
demonstrable preference for binding the PtdIns(3,5)P2 species of PtInds (9). Potent 
compounds exist that specifically target the kinase response for converting PtdIns(3)P to 
PtdIns(3,5)P2, namely Apilomod (10). These compounds should be assessed for efficacy 
in the IFNγ mediated control of norovirus and or Toxoplasma gondii. Third, CUL3 and 
KLHL9 appear to be required for IFNγ control of norovirus, is this also true for T. gondii 
or other intracellular pathogens? Future work will need to assess the role of CUL3 and 
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